


#### **IRDiRC**

INTERNATIONAL RARE DISEASES RESEARCH CONSORTIUM

#### Drug Repurposing Guidebook



#### RARE DISEASES LANDSCAPE AND DRUG REPURPOSING TRENDS








6,000 – 8,000 Diseases are classified as Rare

80% considered Ultra-rare
60% are serious and disabling
50% are life threatening





500 Drugs have reached the market 5% of rare diseases have an approved treatment 700-800 treatments in development



#### TREMENDOUS UNMET MEDICAL NEED

## **IRDiRC's GOAL**

# **1000** new rare disease treatments by 2027

At the current rate of drug development (40-50 new therapies developed per year), it would take **500** years to get a treatment for all rare conditions! Therefore a better means to repurposing drugs for rare diseases is needed

Austin CP, et al., Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective. Clin Transl Sci. 2018 Jan;11(1):21-27



## Drug Repurposing Guidebook

A patient focused guidebook that describes the available tools, incentives, resources and practices for drug repurposing for rare diseases and how to best use them. It can be used by academic, non-profit organizations, small and larger (innovative) biotechs and patient-driven drug developers.

#### DRG – PROJECT AT-A-GLANCE





- 1 Workshop with 27 drug repurposing & RD experts and stakeholders
- 44 Building Blocks (BBs)
- 3 Case Scenarios
- Use of building blocks across the different phases and milestones of drug development
- Roadmap Check-lists of "what to do" and "when to do it"




#### **TECHNICAL EXPERTS AFFILIATIONS**





#### DRG- FRAMEWORK






## DRG – BUILDING BLOCKS (BBS) CLASSIFICATION

For each BB it was created a factsheet describing its relevance to rare disease drug development, availability, scope of use, output, pros and cons of usage, best time to apply, duration and costs ().

#### 44 BBs were identified consisting of:

- Regulatory pathways, designations and incentives for ODD in EU, US and Japan
- HTA and reimbursement practices and procedures to support the economic value proposition and assessment, mainly focused on EU
- Development practices best-practice established by developers in the field of rare diseases, to improve orphan drug development in terms of speed, quality or efficiency
- **Development resources** physical or practical existing accessible resource, to support drug developers in the orphan space



#### **Building Blocks**

Traditional regulatory	PMDA Pre-IND •		End of Phase II meeting	End of P	EMA Pre-submission meeting End of Phase III meeting	
activities		PIP	+	Pre-NDA Antic	/BLA ipate Market Authorisation	
		0-0	→ <b>9</b> → <b>9</b>	<b>→0</b> -	→9-→9-	
Patient's Dise NEED know	ease Target Product discovery	Nonclinical Pop FIH read	dy Human PoC Pivo	tal data MAA NDA/BL		
Engagement with MA				>	Engagement with MA Public-private collaboration Pre-competitive space working	
Contact with TTO and patents		<b>→</b>			Search & use IP & legal db Patent framework DR ▶ TTOs ■ ■ ■ ■ ♠ Literature archiv	
Patient and KOL engagement		+			Patient and KOL engagement EU, US and Japanese CRN EURORDIS' CAB	
Funding					Funding resources for DR Public funding Private funding	
Clinical development, including extrapolation of efficacy and safety data	**********************************	*	* <b>*</b>	-	Dose finding Extrapolation Safety data across indications Combinations of drugs Clinical trial db PKPD modelling in children New formulations of drugs	
Orphan Drug Development		<b>**</b>			ODD	
Regulatory and HTA engagement					JointEMA-HTA SA PUMA ILAP EMA Pilot to support academia STAMP Initiative updating old labels STARS Engaging with HT Pricing models	
Design trials for DR		$\mapsto$			Alternative designs for SPCT	
Availability of data		-+		*	Data outside pr Prevalence dat. NH studies Cure ID Off-label use CDRC DARWIN EU Generics	
Compound and network databases and tools to use them					Chemical compound db Vetwork db EU Open Screen n Silico - VPH Vachine Learning & DM Zompetitive intelligence Drug Prio analysis	
Supporting tools					EATRIS REMEDIAALL wewFound Initiative Remedi REPO4EU Orug Discovery Platform ROADMAP Orug Databases LifeArc	




#### DRG – How do you start the development of your product?

S<br/>TSTakeholders mappingTAAAvailable information on the diseaseRFinancial Resources


Target Patient Value Profile








#### DRG – ENGAGEMENT






#### DRG – REGULATORY & ACCESS



#### DRG – TOOLS AND DATA





#### DRG – TAKE HOME MESSAGES



